Our data from this combined analysis could help us to develop new therapeutic approaches that selectively antagonize CD117/KIT, HER2, and ERβ, or act upon the downstream target genes of these receptors that might be applied individually or in combination to target bladder cancer. The gene discussed is ESR2; the disease is urinary bladder cancer.